Complete End-to-End Knowledge Framework for Computational Drug Development

Most CADD conversations still get stuck at “we do docking and virtual screening.” That’s the bare minimum.

I’ve been working on a Complete End-to-End Knowledge Framework for Computational Drug Development that treats CADD as a lifespan function – from target ideation to Phase III support and regulatory expectations.
Here’s how I’m framing it:

Stage 1 – Target ID & Validation: Human genetics first, not last. Multi‑omics, Mendelian randomisation, tractability, and druggability are assessed in parallel, not sequentially.

Stage 2 – Hit Discovery: Structure‑ and ligand‑based VS, docking rigor (self‑docking, protonation sanity checks, consensus scoring), and clear enrichment strategies before we waste a single HTS plate.
Stage 3 – Hit‑to‑Lead: Systematic triage with ligand efficiency metrics, PAINS/aggregator cleanup, selectivity, and early ADMET filters baked into entry criteria.

Stage 4 – Lead Optimisation: True MPO (not potency worship), FEP/MD for decision‑grade ΔΔG, and consensus in silico ADMET instead of single‑model wishful thinking.

Stage 5 – Candidate Selection: Explicit computational gates for activity, ADMET, PK, physicochemical space, and translational readiness.

Stage 6 – Clinical Support: PBPK, exposure–response, biomarker strategy, and patient‑selection biomarkers feeding back into development, not treated as “nice to have.”

Stage 7 – Cross‑cutting: Data curation, reproducibility, regulatory awareness (ICH M7, PBPK guidance), and disciplined communication so predictions are audit‑ready and decision‑useful.

This framework is Version 1.0, built for CADD training, project planning, and interview prep in an industrial setting. My goal is simple: move the conversation from “we ran a docking campaign” to “we run an evidence‑driven, auditable, end‑to‑end computational strategy that actually de‑risks programs.”

If you’re a CADD / medchem / translational scientist (or building a computational function from scratch), I’m happy to share the framework and walk through how I’d adapt it for:

Early‑stage biotech with limited experimental bandwidth
Big‑pharma environments with heavy legacy data and regulatory scrutiny
Academic–industry collaborations where reproducibility and communication usually break first.

CLICK HERE

Comments

Curated Compendium of Drug Discovery

Drug discovery is a multidisciplinary process that integrates biology, chemistry, pharmacology , and cutting-edge technologies to identify and develop new therapeutic agents. From target identification to lead optimization and clinical evaluation, each stage requires precision, innovation, and collaboration. A curated list of drug discovery resources provides researchers, students, and professionals with a structured pathway to explore advancements, tools, and strategies that shape modern therapeutics. This compilation serves as a gateway to understanding the evolution of drug discovery, recent breakthroughs, and future directions, fostering knowledge-sharing and accelerating translational research. Databases and Chemical Libraries General Compound Libraries DrugBank - Comprehensive data on approved and investigational drugs. ZINC - Free compounds for screening. ChemSpider - Chemical structures and data. DrugSpaceX - Chemical and biological spaces. Mcule ...

Understanding NMR Spectroscopy and Chemical Shift Ranges for Functional Groups

Nuclear Magnetic Resonance ( NMR ) spectroscopy is one of the most powerful analytical tools in pharmaceutical chemistry. It helps chemists determine the structure, purity, and chemical environment of molecules by analyzing the behavior of nuclei (commonly ¹H or ¹³C ) when exposed to a strong magnetic field. In proton NMR ( ¹H-NMR ), the chemical shift (δ, in ppm) provides information about the type of hydrogen atoms present in a compound and their surrounding electronic environment. Depending on nearby atoms and functional groups, signals appear in specific regions of the spectrum — often referred to as upfield (shielded, lower δ values) or downfield (deshielded, higher δ values). The image above summarizes the characteristic δ ranges for different functional groups in ¹H-NMR. Let us break it down systematically: 1. Downfield Region (δ 12 – 6 ppm) Hydrogens in this region are strongly deshielded due to electronegative atoms or π-bond systems. Carboxylic Acids (–COOH) : δ 1...

Pushing the boundaries of computational drug discovery at Isomorphic Labs

The Isomorphic Labs Drug Design Engine (IsoDDE) has unlocked a new frontier in in-silico drug design, representing a significant evolution beyond AlphaFold 3. What IsoDDE delivers: 🔹 Massive accuracy leap on unconstrained structure prediction The engine more than doubles AlphaFold 3's accuracy on extremely challenging protein-ligand prediction tasks — including systems far outside the training distribution. 🔹 Best-in-class binding affinity prediction IsoDDE predicts how strongly small molecules bind to targets with accuracy that exceeds gold-standard physics-based methods, at a fraction of the computational cost and time. 🔹 Blind identification of novel binding pockets Even without existing structural data, the engine reveals previously unseen binding sites — just from an amino acid sequence — enabling drug designers to explore entirely new chemical action spaces. 🔹 Expanded support for complex biologics Beyond small molecules, the engine boosts prediction fidelity for...

NEOPHARMA NUTSHELL COMMUNITY

Search This Blog